 Clinuvel Pharmaceutical has introduced its first commercial product Scenesse in Europe and the US in 2014 and 2019 for the rare disease EPP. Since then, it has stayed very secretive about its future growth pathways, much to the dismay of many investors and the perceived lack of vision had the share price. 